Bristol-Myers Squibb completes $74bn acquisition of biotechnology firm Celgene

Bristol-Myers Squibb completes $74bn acquisition of biotechnology firm Celgene

Submitted by admin on November 21, 2019 - 10:14am
Source: 
Pharmaceutical Business Review
News Tags: 
M&A
Bristol-Myers Squibb
Celgene
Headline: 
Bristol-Myers Squibb completes $74bn acquisition of biotechnology firm Celgene
snippet: 


Bristol-Myers Squibb (BMS) has completed the acquisition of US-based biotechnology company Celgene in a cash-cum-stock deal worth around $74bn.

Do Not Allow Advertisers to Use My Personal information